The Application and Challenges of Artificial Intelligence in G Protein-Coupled Receptor Drug Virtual Screening
DOI:
https://doi.org/10.61173/q2f3vy73Keywords:
Artificial Intelligence, Deep Learning, G Protein-Coupled Receptor, Virtual Screening, Drug DiscoveryAbstract
G protein-coupled receptors play important roles in various diseases and are key targets for drug discovery. Virtual screening has traditionally been used to identify potential drug candidates from large compound libraries but faces challenges in computational resources and time constraints. The integration of artificial intelligence technologies has improved screening precision and reduced costs. This review discusses current developments, challenges, and future directions in leveraging artificial intelligence to advance GPCR drug screening.
References
[1] A.S. Hauser, M.M. Attwood, M. Rask-Andersen, H.B. Schioth, D.E. Gloriam, Trends in GPCR drug discovery: new agents, targets and indications, Nat Rev Drug Discov 16(12) (2017) 829-842.
[2] D.E. Clark, What has virtual screening ever done for drug discovery?, Expert Opin Drug Discov 3(8) (2008) 841-51.
[3] T. Sterling, J.J. Irwin, ZINC 15--Ligand Discovery for Everyone, J Chem Inf Model 55(11) (2015) 2324-37.
[4] J.J. Irwin, K.G. Tang, J. Young, C. Dandarchuluun, B.R. Wong, M. Khurelbaatar, Y.S. Moroz, J. Mayfield, R.A. Sayle, ZINC20-A Free Ultralarge-Scale Chemical Database for Ligand Discovery, J Chem Inf Model 60(12) (2020) 6065-6073.
[5] L. Bellmann, P. Penner, M. Gastreich, M. Rarey, Comparison of Combinatorial Fragment Spaces and Its Application to Ultralarge Make-on-Demand Compound Catalogs, J Chem Inf Model 62(3) (2022) 553-566.
[6] H. Zhang, H. Fan, J. Wang, T. Hou, K.M. Saravanan, W. Xia, H.W. Kan, J. Li, J.Z.H. Zhang, X. Liang, Y. Chen, Revolutionizing GPCR-ligand predictions: DeepGPCR with experimental validation for high-precision drug discovery, Brief Bioinform 25(4) (2024).
[7] T. Sanavia, G. Birolo, L. Montanucci, P. Turina, E. Capriotti, P. Fariselli, Limitations and challenges in protein stability prediction upon genome variations: towards future applications in precision medicine, Comput Struct Biotechnol J 18 (2020) 1968-1979.
[8] J. Vamathevan, D. Clark, P. Czodrowski, I. Dunham, E. Ferran, G. Lee, B. Li, A. Madabhushi, P. Shah, M. Spitzer, S. Zhao, Applications of machine learning in drug discovery and development, Nat Rev Drug Discov 18(6) (2019) 463-477.
[9] A. Jabeen, S. Ranganathan, Applications of machine learning in GPCR bioactive ligand discovery, Curr Opin Struct Biol 55 (2019) 66-76.
[10] A.J. Kooistra, S. Mordalski, G. Pandy-Szekeres, M. Esguerra, A. Mamyrbekov, C. Munk, G.M. Keseru, D.E. Gloriam, GPCRdb in 2021: integrating GPCR sequence, structure and function, Nucleic Acids Res 49(D1) (2021) D335-D343.
[11] K. Sriram, P.A. Insel, G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?, Molecular pharmacology 93(4) (2018) 251-258.
[12] R.T. Dorsam, J.S. Gutkind, G-protein-coupled receptors and cancer, Nat Rev Cancer 7(2) (2007) 79-94.
[13] Y. Huang, N. Todd, A. Thathiah, The role of GPCRs in neurodegenerative diseases: avenues for therapeutic intervention, Curr Opin Pharmacol 32 (2017) 96-110.
[14] J. Zhou, C. Wild, GPCR Drug Discovery: Emerging Targets, Novel Approaches and Future Trends, Curr Top Med Chem 19(16) (2019) 1363-1364.
[15] L.A. Capote, R.M. Perez, A. Lymperopoulos, GPCR signaling and cardiac function, European journal of pharmacology 763 (2015) 143-148.
[16] T.I. Oprea, C.G. Bologa, S. Brunak, A. Campbell, G.N. Gan, A. Gaulton, S.M. Gomez, R. Guha, A. Hersey, J. Holmes, Unexplored therapeutic opportunities in the human genome, Nature reviews Drug discovery 17(5) (2018) 317-332.
[17] C.S. Odoemelam, B. Percival, H. Wallis, M.-W. Chang, Z. Ahmad, D. Scholey, E. Burton, I.H. Williams, C.L. Kamerlin, P.B. Wilson, G-Protein coupled receptors: structure and function in drug discovery, RSC advances 10(60) (2020) 36337-36348.
[18] I. Shimada, T. Ueda, Y. Kofuku, M.T. Eddy, K. Wüthrich, GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures, Nature Reviews Drug Discovery 18(1) (2019) 59-82.
[19] M.J. Robertson, J.G. Meyerowitz, G. Skiniotis, Drug discovery in the era of cryo-electron microscopy, Trends Biochem Sci 47(2) (2022) 124-135.
[20] M. Zhang, T. Chen, X. Lu, X. Lan, Z. Chen, S. Lu, G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery, Signal Transduct Target Ther 9(1) (2024) 88.
[21] R. Gupta, D. Srivastava, M. Sahu, S. Tiwari, R.K. Ambasta, P. Kumar, Artificial intelligence to deep learning: machine intelligence approach for drug discovery, Molecular diversity 25 Dean&Francis (2021) 1315-1360.
[22] Y. Jing, Y. Bian, Z. Hu, L. Wang, X.-Q.S. Xie, Deep learning for drug design: an artificial intelligence paradigm for drug discovery in the big data era, The AAPS journal 20 (2018) 1-10.
[23] L. Breiman, Random forests, Machine learning 45 (2001) 5-32.
[24] G.I. Webb, E. Keogh, R. Miikkulainen, Naïve Bayes, Encyclopedia of machine learning 15(1) (2010) 713-714.
[25] K.-K. Mak, Y.-H. Wong, M.R. Pichika, Artificial intelligence in drug discovery and development, Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays (2023) 1-38.
[26] Enamine, REAL database, pp. https://enamine.net/ compound-collections/real-compounds/real-database.
[27] Enamine, REAL Space, pp. https://enamine.net/compoundcollections/real-compounds/real-space-navigator.
[28] G. Sliwoski, S. Kothiwale, J. Meiler, E.W. Lowe, Computational methods in drug discovery, Pharmacological reviews 66(1) (2014) 334-395.
[29] M. Schlander, K. Hernandez-Villafuerte, C.-Y. Cheng, J. Mestre-Ferrandiz, M. Baumann, How much does it cost to research and develop a new drug? A systematic review and assessment, Pharmacoeconomics 39 (2021) 1243-1269.
[30] P. Schneider, W.P. Walters, A.T. Plowright, N. Sieroka, J. Listgarten, R.A. Goodnow Jr, J. Fisher, J.M. Jansen, J.S. Duca, T.S. Rush, Rethinking drug design in the artificial intelligence era, Nature reviews drug discovery 19(5) (2020) 353-364.
[31] P.C. Tiwari, R. Pal, M.J. Chaudhary, R. Nath, Artificial intelligence revolutionizing drug development: Exploring opportunities and challenges, Drug Development Research 84(8) (2023) 1652-1663.
[32] S. D’Souza, K. Prema, S. Balaji, Machine learning models for drug–target interactions: current knowledge and future directions, Drug Discovery Today 25(4) (2020) 748-756.
[33] V. Casadó, V. Casadó-Anguera, What are the current trends in G protein-coupled receptor targeted drug discovery?, Expert opinion on drug discovery 18(8) (2023) 815-820.
[34] J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figurnov, O. Ronneberger, K. Tunyasuvunakool, R. Bates, A. Žídek, A. Potapenko, Highly accurate protein structure prediction with AlphaFold, nature 596(7873) (2021) 583-589.
[35] H.K. Wayment-Steele, S. Ovchinnikov, L. Colwell, D. Kern, Prediction of multiple conformational states by combining sequence clustering with AlphaFold2, BioRxiv (2022) 2022.10. 17.512570.
[36] W. Chen, C. Song, L. Leng, S. Zhang, S. Chen, The Application of Artificial Intelligence Accelerates G Protein- Coupled Receptor Ligand Discovery, Engineering (2023).
[37] M. Tang, C. Wen, J. Lin, H. Chen, T. Ran, Discovery of novel A2AR antagonists through deep learning-based virtual screening, Artificial Intelligence in the Life Sciences 3 (2023) 100058.
[38] M. Wang, S. Hou, Y. Wei, D. Li, J. Lin, Discovery of novel dual adenosine A1/A2A receptor antagonists using deep learning, pharmacophore modeling and molecular docking, PLoS computational biology 17(3) (2021) e1008821.
[39] F. Gentile, V. Agrawal, M. Hsing, A.-T. Ton, F. Ban, U. Norinder, M.E. Gleave, A. Cherkasov, Deep docking: a deep learning platform for augmentation of structure based drug discovery, ACS central science 6(6) (2020) 939-949.
[40] T.B. Kimber, Y. Chen, A. Volkamer, Deep learning in virtual screening: recent applications and developments, International journal of molecular sciences 22(9) (2021) 4435.
[41] A.S. Rifaioglu, H. Atas, M.J. Martin, R. Cetin-Atalay, V. Atalay, T. Doğan, Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases, Briefings in bioinformatics 20(5) (2019) 1878- 1912.
[42] A.T. Nguyen, D.T. Nguyen, H.Y. Koh, J. Toskov, W. MacLean, A. Xu, D. Zhang, G.I. Webb, L.T. May, M.L. Halls, The application of artificial intelligence to accelerate G protein‐coupled receptor drug discovery, British Journal of Pharmacology 181(14) (2024) 2371-2384.
[43] H. Li, K.S. Leung, M.H. Wong, P.J. Ballester, Improving AutoDock Vina using random forest: the growing accuracy of binding affinity prediction by the effective exploitation of larger data sets, Molecular informatics 34(2‐3) (2015) 115-126.
[44] H. Zhang, T. Zhang, K.M. Saravanan, L. Liao, H. Wu, H. Zhang, H. Zhang, Y. Pan, X. Wu, Y. Wei, DeepBindBC: A practical deep learning method for identifying native-like protein-ligand complexes in virtual screening, Methods 205 (2022) 247-262.
[45] K.A. Carpenter, D.S. Cohen, J.T. Jarrell, X. Huang, Deep learning and virtual drug screening, Future medicinal chemistry 10(21) (2018) 2557-2567.
[46] J.L. Melville, E.K. Burke, J.D. Hirst, Machine learning in virtual screening, Combinatorial chemistry & high throughput screening 12(4) (2009) 332-343.
[47] X. Yang, Y. Wang, R. Byrne, G. Schneider, S. Yang, Concepts of artificial intelligence for computer-assisted drug discovery, Chemical reviews 119(18) (2019) 10520-10594.
[48] N.A. Murugan, G.R. Priya, G.N. Sastry, S. Markidis, Artificial intelligence in virtual screening: Models versus experiments, Drug Discovery Today 27(7) (2022) 1913-1923.
[49] T. Burki, A new paradigm for drug development, The Lancet Digital Health 2(5) (2020) e226-e227.
[50] A. IT, Inside the nascent industry of AI-designed drugs, Nature medicine 29 (2023) 1292-1295.
[51] Exscientia, Exscientia Reports Topline Data From EXS- 21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers, pp. https://investors. exscientia.ai/press-releases/press-release-details/2022/ Exscientia-Reports-Topline-Data-From-EXS-21546-Phase- Dean&Francis 1a-Study-Demonstrating-Targeted-A2A-Receptor-Signaling- Inhibition-in-Healthy-Volunteers/default.aspx.
[52] M.C. Lagerström, H.B. Schiöth, Structural diversity of G protein-coupled receptors and significance for drug discovery, Nature reviews Drug discovery 7(4) (2008) 339-357.
[53] Y.-R. Cho, M. Kang, Interpretable machine learning in bioinformatics, Methods (San Diego, Calif.) 179 (2020) 1-2.
[54] M. Volkov, J.-A. Turk, N. Drizard, N. Martin, B. Hoffmann, Y. Gaston-Mathé, D. Rognan, On the frustration to predict binding affinities from protein–ligand structures with deep neural networks, Journal of medicinal chemistry 65(11) (2022) 7946- 7958.
[55] L. Chen, A. Cruz, S. Ramsey, C.J. Dickson, J.S. Duca, V. Hornak, D.R. Koes, T. Kurtzman, Hidden bias in the DUD-E dataset leads to misleading performance of deep learning in structure-based virtual screening, PloS one 14(8) (2019) e0220113.
[56] J. Yang, C. Shen, N. Huang, Predicting or pretending: artificial intelligence for protein-ligand interactions lack of sufficiently large and unbiased datasets, Frontiers in pharmacology 11 (2020) 69.
[57] G. Zhang, Q. Tang, P. Feng, W. Chen, IPs-GRUAtt: an attention-based bidirectional gated recurrent unit network for predicting phosphorylation sites of SARS-CoV-2 infection, Molecular Therapy-Nucleic Acids 32 (2023) 28-35.
[58] Q. Tang, F. Nie, Q. Zhao, W. Chen, A merged molecular representation deep learning method for blood–brain barrier permeability prediction, Briefings in Bioinformatics 23(5) (2022) bbac357.
[59] Q. Bai, S. Liu, Y. Tian, T. Xu, A.J. Banegas‐Luna, H. Pérez‐ Sánchez, J. Huang, H. Liu, X. Yao, Application advances of deep learning methods for de novo drug design and molecular dynamics simulation, Wiley Interdisciplinary Reviews: Computational Molecular Science 12(3) (2022) e1581.
[60] C. Li, J. Liu, J. Chen, Y. Yuan, J. Yu, Q. Gou, Y. Guo, X. Pu, An interpretable convolutional neural network framework for analyzing molecular dynamics trajectories: A case study on functional states for g-protein-coupled receptors, Journal of Chemical Information and Modeling 62(6) (2022) 1399-1410.
[61] M. Matic, G. Singh, F. Carli, N. De Oliveira Rosa, P. Miglionico, L. Magni, J.S. Gutkind, R.B. Russell, A. Inoue, F. Raimondi, PRECOGx: exploring GPCR signaling mechanisms with deep protein representations, Nucleic Acids Research 50(W1) (2022) W598-W610.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
